Lv4
426 积分 2023-11-11 加入
[Cancer statistics in China, 2016]
9小时前
已关闭
Understanding and managing the possible adverse effects associated with bevacizumab
14天前
已完结
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)
14天前
已完结
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
14天前
已完结
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
14天前
已完结
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
14天前
已完结
Onco-Hypertension: Changing Paradigm of Treating Hypertension in Patients With Cancer
18天前
已完结
12 Hyperlipidemia from Sirolimus: Adverse Impact on Development of Cardiac Allograft Vasculopathy
18天前
已关闭
Ceritinib
21天前
已完结
Ceritinib
30天前
已完结
皖公网安备34019202002308
